background
background
hero avatar

Redefining What’s Possible in Pet Health

Each program in our pipeline is built on disciplined science, thoughtful engineering, and a commitment to advancing care for companion animals.

Using our Ambifect® Fc-fusion protein platform, Akston generates novel protein therapeutics that deliver customized, long-acting agents for a wide variety of diseases.

In our pipeline:
TARGETED PRECISION PROTEINS & IMMUNO-ENHANCING PROTEINS

Targeted precision proteins

Therapeutic proteins that last longer for
obesity and cancer

  • Once-a-week vs twice-a-day
  • Better coverage = better outcomes
  • Lower overall cost of care

Immuno-enhancing proteins

Convenient, low-cost alternatives to monoclonal antibodies (mAbs) for chronic pain, dermatitis, and cancer

  • Twice-a-year vs once-a-month
  • 50x less material than mAbs
  • Single product for all weight classes
Laboratory Target Animal Target Disease Regulatory Submission Market
AKS-701d
CANINE ONCOLOGY

Anti-PD-L1 Monoclonal antibody

AKS-562c
FELINE OBESITY

FcRn recycled GLP-1 for once-a-week dosing

CONFIDENTIAL
CANINE OBESITY

Brown adipose tissue recruitment

AKS-197d
CANINE ONCOLOGY

Insulin growth factor receptor downregulation

AKS-427c
FELINE ONCOLOGY

Insulin growth factor receptor downregulation

AKS-548d
CANINE CHRONIC PAIN

Anti-NGF Ambifect

AKS-637d
CANINE ATOPIC DERMATITIS

Anti-IL-31 Ambifect

AKS-616d
CANINE ONCOLOGY

Anti-PD-L1 Ambifect

SPOTLIGHT: AKS-562c

FELINE OBESITY

FcRn recycled GLP-1 for
once-a-week dosing

SPOTLIGHT: AKS-548d

CANINE CHRONIC PAIN

NGF immunotherapy

Stay informed about our latest updates.

We’re all in on pet health

See how we do it

close